- idUS
- Listar por autor
Listar por autor "Albanell, Joan"
Mostrando ítems 1-2 de 2
-
Artículo
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor-positive, HER2-negative, node-negative early-stage breast cancer
Martín, Miguel; González-Rivera, Milagros; Morales, Serafín; De La Haba-Rodriguez, Juan; González-Cortijo, Lucía; Manso, Luis; Albanell, Joan; Cruz Merino, Luis de la; Prat, Aleix (Taylor and Francis Group, 2015)Purpose: Improved understanding of risk of recurrence (ROR) is needed to reduce cases of recurrence and more effectively ...
-
Artículo
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
Tibau, Ariadna; Martínez, M. Teresa; Ramos, Manuel; Cruz Merino, Luis de la; Santaballa, Ana; O’Connor, Miriam; Albanell, Joan (Sage Journals, 2023)Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression free survival (PFS) compared ...